Sidney Lupkin

Speaking to reporters Tuesday, President Trump said McCary would be leaving and that a deputy would take over FDA temporarily.

During his tenure at the agency, McCary at times angered the Make America Healthy Again movement for not advancing its agenda quickly enough.

Many Maha supporters were upset when the agency approved updated COVID-19 vaccines last year.

McCary also disappointed people who oppose abortion by not completing a promised safety review of mifepristone.

Meanwhile, he faced criticism from those looking for a more predictable approach to FDA regulation.

Before joining the Trump administration, McCary was a surgeon and health policy researcher at Johns Hopkins University School of Medicine.

Sydney Lepkin, NPR News.

The Food and Drug Administration approved a Wagovi pill at the end of 2025, and it will become available this year.

A competing pill made by Eli Lilly could soon follow.

Meanwhile, direct-to-consumer GLP-1s sold by the drug companies to patients who don't use their insurance could continue to grow in popularity.

Those discounted prices have dropped over time.

But the drug's sticker prices haven't dropped, and insurance coverage for the injectables has actually gotten more restrictive when it comes to weight loss.

For example, some plans only cover obesity drugs for patients with a body mass index over 40, even though obesity is classified as having a BMI of 30 or higher.

Sidney Lepkin, NPR News.

Yeah, the administration says it can do a better job at negotiating the prices Medicare pays for drugs. It's not clear from the action exactly how that would be the case. And I have to say that a lot of the savings on drug prices are

Yeah, the administration says it can do a better job at negotiating the prices Medicare pays for drugs. It's not clear from the action exactly how that would be the case. And I have to say that a lot of the savings on drug prices are

Yeah, the administration says it can do a better job at negotiating the prices Medicare pays for drugs. It's not clear from the action exactly how that would be the case. And I have to say that a lot of the savings on drug prices are

baked into the biden administration law that gave medicare negotiating power in the first place it allowed 10 drugs to be negotiated last year and 15 more this year next year another 15 should be up for negotiation so over time the savings should add up but the executive action asks the health secretary and congress to fix what the administration sees as a flaw in the law

baked into the biden administration law that gave medicare negotiating power in the first place it allowed 10 drugs to be negotiated last year and 15 more this year next year another 15 should be up for negotiation so over time the savings should add up but the executive action asks the health secretary and congress to fix what the administration sees as a flaw in the law

baked into the biden administration law that gave medicare negotiating power in the first place it allowed 10 drugs to be negotiated last year and 15 more this year next year another 15 should be up for negotiation so over time the savings should add up but the executive action asks the health secretary and congress to fix what the administration sees as a flaw in the law